157 related articles for article (PubMed ID: 30766891)
1. Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients.
Ji LS; Gao QT; Guo RW; Zhang X; Zhou ZH; Yu Z; Zhu XJ; Gao YT; Sun XH; Gao YQ; Li M
J Immunol Res; 2019; 2019():8983903. PubMed ID: 30766891
[TBL] [Abstract][Full Text] [Related]
2. Beneficial Effects of Bushen Formula Combined with Enticavir on Chronic Hepatitis B Patients with Suboptimal Response to Enticavir by Regulating B-Cell Differentiation.
Li M; Zhou ZH; Bao T; Zhang X; Zhu XJ; Jin SG; Gao YT; Sun XH; Gao YQ
Cell Physiol Biochem; 2018; 48(2):633-643. PubMed ID: 30025397
[TBL] [Abstract][Full Text] [Related]
3. Bushen Formula promotes the decrease of HBsAg levels in patients with CHB by regulating Tfh cells and B-cell subsets.
Ji L; Wei J; Zhang R; Zhang X; Gao Y; Fang M; Yu Z; Cao L; Gao Y; Li M
J Ethnopharmacol; 2024 Jun; 328():118072. PubMed ID: 38508431
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
[TBL] [Abstract][Full Text] [Related]
5. Partial virological response to entecavir treatment in nucleos(t)ide-naïve patients with HBeAg-positive chronic hepatitis B is not caused by reduced sensitivity.
Li X; Li F; Zhang Y; Kang Y; Yu J; Yang F; Liu H; Qin Y; Huang Y; Mao R; Zhang J
Biochem Biophys Res Commun; 2015 Sep; 464(4):1185-1191. PubMed ID: 26212437
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
7. Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B.
Li M; Gao Y; Yang L; Lin Y; Deng W; Jiang T; Bi X; Lu Y; Zhang L; Shen G; Liu R; Wu S; Chang M; Xu M; Hu L; Song R; Jiang Y; Yi W; Xie Y
Front Immunol; 2022; 13():1024333. PubMed ID: 36203581
[TBL] [Abstract][Full Text] [Related]
8. Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China.
Li X; Zhang L; Qiu M; Huang Y; Xiao H; Lu B; Jiang Y; Long F; Lin H; He J; Wu Q; Zhang M; Wang L; Zhu X; Gong M; Sun X; Sun J; Sun F; Lu W; Xu W; Chen G; Li Z; Gan D; Yang X; Du H; Ye Y
Trials; 2020 Aug; 21(1):708. PubMed ID: 32787905
[TBL] [Abstract][Full Text] [Related]
9. Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.
Wang YH; Liao J; Zhang DM; Wu DB; Tao YC; Wang ML; Chen EQ; Tang H
J Med Virol; 2020 Mar; 92(3):302-308. PubMed ID: 31609007
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
[TBL] [Abstract][Full Text] [Related]
11. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.
Kayaaslan B; Akinci E; Ari A; Tufan ZK; Alpat SN; Gunal O; Tosun S; Guner R; Tabak F
Clin Res Hepatol Gastroenterol; 2018 Feb; 42(1):40-47. PubMed ID: 28757048
[TBL] [Abstract][Full Text] [Related]
12. Changes in the balance between Treg and Th17 cells in patients with chronic hepatitis B.
Su ZJ; Yu XP; Guo RY; Ming DS; Huang LY; Su ML; Deng Y; Lin ZZ
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):437-44. PubMed ID: 23747030
[TBL] [Abstract][Full Text] [Related]
13. Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial.
Ye YA; Li XK; Zhou DQ; Chi XL; Li Q; Wang L; Lu BJ; Mao DW; Wu QK; Wang XB; Zhang MX; Xue JD; Li Y; Lu W; Guo JC; Jiang F; Zhang XW; Du HB; Yang XZ; Guo H; Gan DN; Li ZG
Chin J Integr Med; 2018 Sep; 24(9):653-660. PubMed ID: 30209792
[TBL] [Abstract][Full Text] [Related]
14. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study.
Batirel A; Guclu E; Arslan F; Kocak F; Karabay O; Ozer S; Turanli M; Mert A
Int J Infect Dis; 2014 Nov; 28():153-9. PubMed ID: 25286184
[TBL] [Abstract][Full Text] [Related]
15. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
16. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
[TBL] [Abstract][Full Text] [Related]
17. Clinical and virological outcomes of entecavir therapy in patients with chronic hepatitis B: A real life experience.
Aljumah AA; Bin Selayem NA; Al-Howti SY; Dafallah M; AlGhamdi H; Mokhtar H; Albekairy AM; Sanai FM
J Infect Chemother; 2019 Jan; 25(1):12-16. PubMed ID: 30366861
[TBL] [Abstract][Full Text] [Related]
18. Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: a pilot study.
Du QW; Ding JG; Sun QF; Hong L; Cai FJ; Zhou QQ; Wu YH; Fu RQ
Med Sci Monit; 2013 Sep; 19():751-6. PubMed ID: 24019010
[TBL] [Abstract][Full Text] [Related]
19. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response.
Zoutendijk R; Reijnders JG; Brown A; Zoulim F; Mutimer D; Deterding K; Petersen J; Hofmann WP; Buti M; Santantonio T; van Bömmel F; Pradat P; Oo Y; Luetgehetmann M; Berg T; Hansen BE; Wedemeyer H; Janssen HL;
Hepatology; 2011 Aug; 54(2):443-51. PubMed ID: 21563196
[TBL] [Abstract][Full Text] [Related]
20. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
